Second Sight Medical Products Inc
Change company Symbol lookup
Select an option...
EYES Second Sight Medical Products Inc
MCBS MetroCity Bankshares Inc
GNBT Generex Biotechnology Corp
XOM Exxon Mobil Corp
T AT&T Inc
BAC Bank of America Corp
VTI Vanguard Total Stock Market Index Fund ETF Shares
GE General Electric Co
AAL American Airlines Group Inc
HD Home Depot Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Health Care Equipment & Supplies | Small Cap BlendCompany profile

Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company intends to develop Orion Visual Cortical Prosthesis which provides useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease or forms of cancer and trauma. Its product, The Argus II Retinal Prosthesis System (The Argus II) provides electrical stimulation of the retina to induce visual perception in blind individuals and helps in treating outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. The Company's Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals.

Closing Price
$0.77
Day's Change
-0.0499 (-6.09%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.81
Day's Low
0.76
Volume
(Light)
Volume:
107,546

10-day average volume:
194,140
107,546

Values displayed are in thousands.

2014
12/31/14
2015
12/31/15
2016
12/31/16
2017
12/31/17
2018
12/31/18
Total Revenue3,3988,9503,9857,9646,896

Values displayed are in thousands.

2014
12/31/14
2015
12/31/15
2016
12/31/16
2017
12/31/17
2018
12/31/18
Cost of Revenue, Total3,5585,29310,0765,1174,888
Selling/Gen/Admin Expense15,04218,46819,02020,30223,700
Labor & Related Expense9912,2002,7523,2612,928
Sell/Gen/AdminExpenses,Tot16,03220,66821,77223,56326,628
Research & Development5,0413,0365,3477,89310,005
Restructuring Charge--------555
Other Unusual Expnse (In)6,95500----
Unusual Expense (Income)6,95500--555
Total Operating Expense31,58628,99737,19536,57342,076

Values displayed are in thousands.

2014
12/31/14
2015
12/31/15
2016
12/31/16
2017
12/31/17
2018
12/31/18
Total Operating Income(28,188)(20,047)(33,210)(28,609)(35,180)

Values displayed are in thousands.

2014
12/31/14
2015
12/31/15
2016
12/31/16
2017
12/31/17
2018
12/31/18
Inter Expse,Net Non-Operat(7,034)00----
Inter/Invest Inc, Non-Oper92319386
OtherNon-OperatInc (Expnse)122700--
Other, Net122700--
Income Before Tax(35,201)(20,018)(33,179)(28,516)(35,094)

Values displayed are in thousands.

2014
12/31/14
2015
12/31/15
2016
12/31/16
2017
12/31/17
2018
12/31/18
Income Tax - Total------0--
Income After Tax(35,201)(20,018)(33,179)(28,516)(35,094)

Values displayed are in thousands.

2014
12/31/14
2015
12/31/15
2016
12/31/16
2017
12/31/17
2018
12/31/18
Net Inc Before Extra Items(35,201)(20,018)(33,179)(28,516)(35,094)

Values displayed are in thousands.

2014
12/31/14
2015
12/31/15
2016
12/31/16
2017
12/31/17
2018
12/31/18
Total Extraordinary Items------0--

Values displayed are in thousands.

2014
12/31/14
2015
12/31/15
2016
12/31/16
2017
12/31/17
2018
12/31/18
Total Net Income(35,201)(20,018)(33,179)(28,516)(35,094)

Values displayed are in thousands.

2014
12/31/14
2015
12/31/15
2016
12/31/16
2017
12/31/17
2018
12/31/18
Income Available to Common Excl. Extra. Items(35,201)(20,018)(33,179)(28,516)(35,094)
Income Available to Common Incl. Extra. Items(35,201)(20,018)(33,179)(28,516)(35,094)

Values displayed are in thousands.

2014
12/31/14
2015
12/31/15
2016
12/31/16
2017
12/31/17
2018
12/31/18
Basic/Primary Weighted Average Shares25,05335,63739,55454,15266,378
Basic/Primary EPS Excl. Extra. Items(1.41)(0.56)(0.84)(0.53)(0.53)
Basic/Primary EPS Incl. Extra. Items(1.41)(0.56)(0.84)(0.53)(0.53)
Diluted Weighted Average Shares25,05335,63739,55454,15266,378
Diluted EPS Excl. Extra. Items(1.41)(0.56)(0.84)(0.53)(0.53)
Diluted EPS Incl. Extra. Items(1.41)(0.56)(0.84)(0.53)(0.53)

Values displayed are in thousands.

2014
12/31/14
2015
12/31/15
2016
12/31/16
2017
12/31/17
2018
12/31/18
Div/Share-ComStockPrimIssue0.000.000.000.00--
Gross Divid - Common Stock00000

Values displayed are in thousands.

2014
12/31/14
2015
12/31/15
2016
12/31/16
2017
12/31/17
2018
12/31/18
Pro Forma Net Income----------

Values displayed are in thousands.

2014
12/31/14
2015
12/31/15
2016
12/31/16
2017
12/31/17
2018
12/31/18
Interest Expense, Suppl7,03400----
Depreciat/Amort, Suppl279335432457435

Values displayed are in thousands.

2014
12/31/14
2015
12/31/15
2016
12/31/16
2017
12/31/17
2018
12/31/18
Total Special Items6,95500--555
Normalzd Income Before Tax(28,247)(20,018)(33,179)(28,516)(34,539)
Efct/SpecItemsIncTxs (STEC)000--0
IncTxsExcl ImpctofSpec Itms00000
Normalized Income After Tax(28,247)(20,018)(33,179)(28,516)(34,539)
Normalzd Inc Avail to Common(28,247)(20,018)(33,179)(28,516)(34,539)
Basic Normalized EPS(1.13)(0.56)(0.84)(0.53)(0.52)
Diluted Normalized EPS(1.13)(0.56)(0.84)(0.53)(0.52)
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2019. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.